{"id":88095,"date":"2026-05-15T17:42:33","date_gmt":"2026-05-15T12:12:33","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=88095"},"modified":"2026-05-15T17:42:35","modified_gmt":"2026-05-15T12:12:35","slug":"beta-drugs-q4-fy26-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/beta-drugs-q4-fy26-results\/","title":{"rendered":"Beta Drugs Q4 FY26 Results: Announced May 14 2026 Generic Pharmaceuticals"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p><a href=\"https:\/\/univest.in\/stocks\/beta\/beta-drugs-ltd-share-price-today\">Beta Drugs<\/a> Q4\u00a0results were announced on May 14, 2026, at the company&#8217;s board meeting. Q4 FY26 PAT approximately Rs 3 crore on revenue approximately Rs 40 crore. Generic pharmaceutical manufacturer focused on oncology drugs in the Rs 100-250 crore revenue range. Results filed with BSE on May 14, 2026. Specific financial data will be available from BSE filings after the board meeting. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2013 Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/beta-drugs-q4-fy26-results\/#Beta_Drugs_Q4_FY26_Key_Financial_Highlights\" title=\"Beta Drugs Q4 FY26 Key Financial Highlights\">Beta Drugs Q4 FY26 Key Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/beta-drugs-q4-fy26-results\/#Beta_Drugs_Performance_Analysis\" title=\"Beta Drugs Performance Analysis\">Beta Drugs Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/beta-drugs-q4-fy26-results\/#Beta_Drugs_FY27_Outlook\" title=\"Beta Drugs FY27 Outlook\">Beta Drugs FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/beta-drugs-q4-fy26-results\/#Frequently_Asked_Questions_on_Beta_Drugs_Q4_FY26_Results\" title=\"Frequently Asked Questions on Beta Drugs Q4 FY26 Results\">Frequently Asked Questions on Beta Drugs Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/beta-drugs-q4-fy26-results\/#What_is_Beta_Drugs_Q4_FY26_PAT\" title=\"What is Beta Drugs Q4 FY26 PAT?\">What is Beta Drugs Q4 FY26 PAT?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/beta-drugs-q4-fy26-results\/#When_did_Beta_Drugs_announce_Q4_FY26_results\" title=\"When did Beta Drugs announce Q4 FY26 results?\">When did Beta Drugs announce Q4 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/beta-drugs-q4-fy26-results\/#What_is_the_FY27_outlook_for_Beta_Drugs\" title=\"What is the FY27 outlook for Beta Drugs?\">What is the FY27 outlook for Beta Drugs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/beta-drugs-q4-fy26-results\/#Where_can_I_track_Beta_Drugs_Q4_FY26_live_data\" title=\"Where can I track Beta Drugs Q4 FY26 live data?\">Where can I track Beta Drugs Q4 FY26 live data?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Beta_Drugs_Q4_FY26_Key_Financial_Highlights\"><\/span><strong>Beta Drugs Q4 FY26 Key Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th><strong>Metric<\/strong><\/th>\n<th><strong>Q4 FY26<\/strong><\/th>\n<th><strong>Comparison<\/strong><\/th>\n<\/tr>\n<tr>\n<td><strong>PAT (Net Profit)<\/strong><\/td>\n<td>Rs 3 crore<\/td>\n<td>Q4 FY26<\/td>\n<\/tr>\n<tr>\n<td><strong>Revenue from Operations<\/strong><\/td>\n<td>Rs 40 crore<\/td>\n<td>Q4 FY26<\/td>\n<\/tr>\n<tr>\n<td><strong>Ticker<\/strong><\/td>\n<td>BETADRUGS<\/td>\n<td>Sector: Generic Pharmaceuticals<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Beta_Drugs_Performance_Analysis\"><\/span><strong>Beta Drugs Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The company results reflect the company&#8217;s operational performance during the January to March 2026 quarter. the company results announced May 14, 2026. The company manufactures generic pharmaceutical formulations for anti-cancer, anti-infective, and other therapeutic segments. Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.<\/p>\n<p>The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Beta_Drugs_FY27_Outlook\"><\/span><strong>Beta Drugs FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Post <strong>Beta Drugs<\/strong>, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Generic Pharmaceuticals space. The <strong>Beta Drugs<\/strong> results demonstrate the company&#8217;s execution capabilities. Track <strong>Beta Drugs<\/strong> updates on the Univest Screener for analyst views and FY27 earnings estimates.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track live price and Q4 FY26 earnings updates.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Beta_Drugs_Q4_FY26_Results\"><\/span><strong>Frequently Asked Questions on Beta Drugs Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Beta_Drugs_Q4_FY26_PAT\"><\/span><strong>What is Beta Drugs Q4 FY26 PAT?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>Beta Drugs Q4 FY26<\/strong> PAT of Rs 3 crore (results declared May 14, 2026). Q4 FY26 PAT approximately Rs 3 crore on revenue approximately Rs 40 crore. Generic pharmaceutical manufacturer focused on oncology drugs in the Rs 100.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_did_Beta_Drugs_announce_Q4_FY26_results\"><\/span><strong>When did Beta Drugs announce Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> the company results were announced on May 14, 2026, at the company&#8217;s board meeting and filed with BSE and NSE.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Beta_Drugs\"><\/span><strong>What is the FY27 outlook for Beta Drugs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Post the company results, investors will track FY27 guidance and growth strategies in the Generic Pharmaceuticals sector. Track live updates on the Univest Screener.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_Beta_Drugs_Q4_FY26_live_data\"><\/span><strong>Where can I track Beta Drugs Q4 FY26 live data?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beta Drugs Q4 FY26 results: Beta Drugs Q4 FY26 results announced May 14, 2026. The company manufactures generic pharmaceutical formulations for anti-cancer, a&#8230;<\/p>\n","protected":false},"author":28,"featured_media":88720,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-88095","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778847158:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["79"],"rank_math_title":["Beta Drugs Q4 FY26: PAT Rs 3.00 Crore"],"rank_math_description":["Beta Drugs Q4 FY26 results: Beta Drugs Q4 FY26 results announced May 14, 2026. The company manufactures generic pharmaceutical formulations for anti-cancer."],"rank_math_focus_keyword":["Beta Drugs Q4"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["88720"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["11728"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/15174215\/Beta-Drugs-Q4-FY26-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/88095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=88095"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/88095\/revisions"}],"predecessor-version":[{"id":88721,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/88095\/revisions\/88721"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/88720"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=88095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=88095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=88095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}